Jazz Pharmaceuticals Plc Revenue Growth Rates (JAZZ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Jazz Pharmaceuticals Plc  (NASDAQ: JAZZ)
 

JAZZ's Revenue Growth by Quarter and Year

Jazz Pharmaceuticals Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

JAZZ Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1,208.30
1st Quarter March 1,068.90
FY 2,277.20

JAZZs Annual Revenue
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2025 $ 4,267.59 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2024 $ 4,068.95 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2023 $ 3,834.20 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2022 $ 3,659.37 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2021 $ 3,094.24 millions




JAZZ Revenue second quarter 2026 Y/Y Growth Comment
Jazz Pharmaceuticals Plc reported Revenue increase of 15.55% year on year in the second quarter 2026, to $ 1,208.30 millions, this is lower than Jazz Pharmaceuticals Plc's recent average Revenue improvement of 22.65%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Jazz Pharmaceuticals Plc' s Revenue growth of 15.55% ranks overall at the positon no. 2590 in the second quarter 2026.


JAZZ Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 10.09 % 7.53 % 4.1 %
3rd Quarter September - 6.74 % 8.52 % 3.35 %
2nd Quarter June 15.55 % 2.14 % 6.95 % 2.62 %
1st Quarter March 19.05 % -0.46 % 1.03 % 9.72 %
FY   - 4.88 % 6.12 % -

Financial Statements
Jazz Pharmaceuticals Plc's second quarter 2026 Revenue $ 1,208.30 millions JAZZ's Income Statement
Jazz Pharmaceuticals Plc's second quarter 2025 Revenue $ 1,045.71 millions Quarterly JAZZ's Income Statement


JAZZ Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.38 % 3.15 % 4.09 %
3rd Quarter September - 7.69 % 3.04 % 1.55 %
2nd Quarter June 13.04 % 16.47 % 13.51 % 7.23 %
1st Quarter March -10.77 % -17.49 % -10.87 % -8.16 %
FY (Year on Year)   - 4.88 % 6.12 % -


Back to JAZZ Growth rate Comparisons >> Back to JAZZ Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590

Revenue Y/Y Growth Statistics
High Average Low
119.32 % 22.65 % 0 %
(Dec 31 2012)   (Dec 31 2011)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590
Revenue Y/Y Growth Statistics
High Average Low
119.32 % 22.65 % 0 %
(Dec 31 2012)   (Dec 31 2011)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Jazz Pharmaceuticals Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
35.49 % 5.66 % -39.09 %
(Sep 30 2012)  


JAZZ's II. Quarter Q/Q Revenue Comment
Jazz Pharmaceuticals Plc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 13.04%, to $ 1,208.30 millions, from $1,068.90 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Jazz Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 707.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #707
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #707
Revenue Q/Q Growth Statistics
High Average Low
35.49 % 5.66 % -39.09 %
(Sep 30 2012)  


JAZZ's II. Quarter Q/Q Revenue Comment
Jazz Pharmaceuticals Plc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 13.04%, to $ 1,208.30 millions, from $1,068.90 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Jazz Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 707.


Jazz Pharmaceuticals Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4,601.23 $ 4,438.65 $ 4,267.59 $ 4,157.83 $ 4,086.69
Y / Y Revenue Growth (TTM) 12.59 % 9.2 % 4.88 % 4.14 % 4.52 %
Year on Year Revenue Growth Overall Ranking # 2134 # 676 # 1207 # 1593 # 2201
Seqeuential Revenue Change (TTM) 3.66 % 4.01 % 2.64 % 1.74 % 0.54 %
Seq. Revenue Growth (TTM) Overall Ranking # 2590 # 946 # 1564 # 1319 # 1835


Cumulative Revenue growth Comment
Although Jazz Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 22.65% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.59% year on year, from 9.2% in Mar 31 2026.

In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 676 to 2134.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 317
Overall # 2134

Revenue TTM Y/Y Growth Statistics
High Average Low
119.32 %
 22.65 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590
Cumulative Revenue growth Comment
Although Jazz Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 22.65% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 12.59% year on year, from 9.2% in Mar 31 2026.

In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 676 to 2134.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 317
Overall # 2134

Revenue TTM Y/Y Growth Statistics
High Average Low
119.32 %
22.65 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
JAZZ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions
Milestone Scientific Inc 22.28%$ 22.276 millions
Alpha Teknova Inc 22.05%$ 22.045 millions
X4 Pharmaceuticals Inc21.64%$ 21.642 millions
Exagen Inc 21.63%$ 21.629 millions
Adaptive Biotechnologies Corporation21.53%$ 21.526 millions
Privia Health Group Inc 21.39%$ 21.390 millions
Bionano Genomics Inc 21.36%$ 21.357 millions
Evolus Inc 21.30%$ 21.298 millions
Invivyd Inc 21.20%$ 21.203 millions


About Jazz Pharmaceuticals Plc Revenue Growth Rates (JAZZ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Jazz Pharmaceuticals Plc (CIK 1232524).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001232524-26-000045
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Jazz Pharmaceuticals Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.